1. Generics Bulletin
  2. >>Products
  3. >>Generics

Sandoz: US Oral Solids And Injectables Have Reached Bottom

Novartis Unit Also Aiming To Move Up Value Chain As Standalone Business

 
• By Dean Rudge

Following Novartis’ announcement that it intended to spin-off its Sandoz business into a standalone company, management from both firms commented on several key issues facing Sandoz, including the US pricing and environment and arrangements for manufacturing.

Dollars (Helen Sessions/Alamy Stock Photo)
Are prospects in the US looking for up for generics manufacturers? • Source: Shutterstock (Alamy Stock Photo)

“The US generics oral solids and injectables business has now, we believe, reached a bottom, and with upcoming launches…can return to a growth profile,” Novartis AG CEO Vas Narasimhan has commented, a significant statement made for its Sandoz Inc. unit following significant pricing headwinds across the US generics sector in the last two years.

Narasimhan’s comments came as the originator disclosed plans to spin-off Sandoz into a standalone, publicly traded company, with an eye...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

The Generics Bulletin Top 50, Part Two: Leading Players Leapfrog The Competition

 
• By Dave Wallace

In the second instalment of Generics Bulletin’s Top 50 ranking for 2025, we see plenty of movement among our mid-table collection of companies.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

 
• By Anju Ghangurde

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.

The Generics Bulletin Top 50, Part One: German Giants Rise Up The Ranks

 
• By Dave Wallace

Two leading German generics and biosimilars giants were the big movers in our top ten ranking of off-patent industry leaders for 2025. We reveal the latest developments among the top players in the first instalment of this year’s Generics Bulletin Top 50.

Sun Strikes Further US Price-Fixing Settlement For $200m

 
• By Dave Wallace

The latest development in the long-running US generic price-fixing saga has seen Sun Pharma agree a $200m settlement in connection with an end purchaser action in Pennsylvania.

More from Products

Just One Week To Go! Entry Deadline Looms For GGB Awards 2025

 
• By Dave Wallace

There is now just one week left to submit entries to the Global Generics & Biosimilars Awards 2025, with the entry deadline set for August 1.

UK Xtandi Patent Stands Strong As Accord, Sandoz, Teva Lose Appeal

 
• By Dean Rudge

The Court of Appeal in London has upheld a key UK patent shielding Astellas’ Xtandi, rejecting claims by a trio of generic drugmakers that it was obvious after finding that the generics firms’ expert analysis was tainted by hindsight.

Biocon Biologics ‘Strategically’ Expands Enbrel Biosimilar With A Launch In Australia

 
• By Urtė Fultinavičiūtė

After acquiring a solid biosimilars business from Viatris, Biocon Biologics has ticked off another market for its Nepexto (etanercept).